Frequency of genetic mutations associated with thromboembolism in the Western Black Sea Region

Internal Medicine

Volumn 50, Issue 1, 2011, Pages 17-21

  Tug, Esra ^a   Aydin, Hatip ^a   Kaplan, Ebru ^a   Dogruer, Dilek ^a  

^a ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

Author keywords

Thromboembolism factor V gene prothrombin gene methylene tetrahydrofolate reductase genegenetic mutation

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; GENOMIC DNA; PROTHROMBIN;

ADULT; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; EARLY DIAGNOSIS; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; RECURRENT ABORTION; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHILIA; TURKEY (REPUBLIC); VASCULAR HEADACHE;

ADULT; AGED; ALLELES; FACTOR V; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; PROTHROMBIN; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA; TURKEY;

EID: 78651243334     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4144     Document Type: Article

References (23)

1. Dahlbäck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 112: 19-27, 2008.
2. März W, Nauck M, Wieland H. The molecular mechanisms of inherited thrombophilia. Z Kardiol 89: 575-586, 2000.
3. Carp H, Salomon O, Seidman D, Dardik R, Rosenberg N, Inbal A. Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. Hum Reprod 17: 1633-1637, 2002.
4. Coulam CB, Wallis D, Weinstein J, DasGupta DS, Jeyendran RS. Comparison of thrombophilic gene mutations among patients experiencing recurrent miscarriage and deep vein thrombosis. Am J Reprod Immunol 60: 426-431, 2008.
5. Koksal V, Baris I, Etlik O. Primer-engineered multiplex PCRRFLP for detection of MTHFR C677T, prothrombin G20210A and factor V Leiden mutations. Exp Mol Pathol 83: 1-3, 2007.
6. Taymaz H, Erarslan S, Oner ET, Alkan T, Agirbasli M, Kirdar B. Sequence variations within the genes related to hemostatic imbalance and their impact on coronary artery disease in Turkish population. Thromb Res 119: 55-62, 2007.
7. Ozmen F, Ozmen MM, Ozalp N, Akar N. The prevalence of factor V (G1691A), MTHFR (C677T) and PT (G20210A) gene mutations in arterial thrombosis. Ulus Travma Acil Cerrahi Derg (Turkish J Trauma & Emergency Surgery) 15: 113-119, 2009.
8. Gurgey A, Mesci L, Renda Y, Olcay L, Kocak N, Erdem G. Factor V Q 506 mutation in children with thrombosis. Am J Hematol 53: 37-39, 1996.
9. Akar N, Akar E, Dalgin G, Sözüöz A, Omürlü K, Cin S. Frequency of Factor V (1691 G → A) mutation in Turkish population. Thromb Haemost 78: 1527-1528, 1997.
10. Segers K, Dahlback B, Nicolaes GA. Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost 98: 530-542, 2007.
11. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 346: 1133-1134, 1995.
12. Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE, Peake IR. High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol 88: 219-222, 1994.
13. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 353: 1167-1173, 1999.
14. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism: pooled analysis of 8 case-control studies including 2310 cases and 3204 controls: Study group for pooledanalysis in venous thromboembolism. Thromb Haemost 86: 809-816, 2001.
15. Gul A, Ozbek U, Ozturk C, Inanc M, Konice M, Ozcelik T. Coagulation factor V gene mutation increases the risk of venous thrombosis in behçet's disease. Br J Rheumatol 35: 1178-1180, 1996.
16. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79: 706-708, 1998.
17. Akar N, Misirlioglu M, Akar E, Avcu F, Yalçin A, Sözööz A. Prothrombin gene 20210 G-A mutation in the Turkish population. Am J Hematol 58: 249, 1998.
18. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10: 111-113, 1995.
19. Sotiriadis A, Vartholomatos G, Pavlou M, et al. Combined thrombophilic mutations in women with unexplained recurrent miscarriage. Am J Reprod Immunol 57: 133-141, 2007.
20. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: The Copenhagen City Heart Study and 2 metaanalyses. Blood 100: 3-10, 2002.
21. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 146: 948-957, 2003.
22. Mueller T, Marschon R, Dieplinger B, et al. Factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations are not associated with chronic limb ischemia: the Linz Peripheral Arterial Disease (LIPAD) study. J Vasc Surg 41: 808-815, 2005.
23. Jensen R. Clinical presentation of arterial thrombosis vs. venous thrombosis. Clin Hemost 8: 1-6, 2002.